ENG
ESP
Immunological response to vaccination and risk of COVID-19 in adults with hematological malignancies
Jorge Alberto Cortes- Laura Cristina Nócua-Báez
- Candida Díaz-Brochero
- Sonia Isabel Cuervo-Maldonado
Published 2023-06-30
How to Cite
Copyright (c) 2023 Jorge Alberto Cortes, Laura Cristina Nócua-Báez, Candida Díaz-Brochero, Sonia Isabel Cuervo-Maldonado
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Patients with hematological malignancies have a higher risk of hospital admission, critical care and death when they suffer from COVID-19. In this group of patients, vaccination and boosters have been proposed to mitigate the risk of complications. However, it is possible to observe a diminished rate of humoral and cellular response. In this review, evidence is shown about the response to COVID-19 vaccination, considering some specific pathologies and treatments that can affect such response in a significant account. Patients with malignant neoplasm must be considered at risk of COVID-19 complications, even after a complete vaccine schedule and boosters. Surveillance must be maintained after vaccination over these patients and other strategies must be considered (drugs, monoclonal antibodies) for prevention and management of COVID-19.